Standard Versus Dose Reduced Chemoradiotherapy in Anal Cancer: Short Term Results of the PhaseII PLATO-ACT4 Randomised Controlled Trial (RCT) ISRCTN88455282
Alexandra Gilbert(St James's University Hospital), Mark Harrison(Hillingdon Hospitals NHS Foundation Trust), Andrew G. Renehan(University of Manchester), Lindy Berkman, Natalie L. Abbott(St Bartholomew's Hospital), Shaharyar M. Khan(Royal Sussex County Hospital), Richard Adams(Velindre Cancer Centre), Henry M. Wood(University of Leeds), Joanne Copeland(University of Leeds), M. Hawkins(University College Hospital), Susan D. Richman(University of Leeds), David Sebag‐Montefiore(University of Leeds), Rob Glynne‐Jones(Mount Vernon Cancer Centre), Vicky Goh(King's College London), Sarah Brown(University of Leeds), Duncan C. Gilbert(Royal Sussex County Hospital), Daniel Bottomley(University of Leeds), Alexandra Stewart(Royal Surrey County Hospital), Sheela Rao(Royal Marsden NHS Foundation Trust), Sharon Ruddock(University of Leeds), Nathalie Casanova(St James's University Hospital), Alexandra Smith(University of Leeds), R. Muirhead(Churchill Hospital), Stephen A. Falk(At Bristol), Webster Joanne(University of Leeds), Max Whibley(Royal Sussex County Hospital)
Cited by 3
Related Papers
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k